March 25th 2023
This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.
February 2nd 2023
January 31st 2023
January 30th 2023
Valneva Successfully Completes Chikungunya Vaccine Phase 3 TrialMarch 8th 2022
There is no vaccine to prevent or treat chikungunya virus. Valneva announced 98.9% of phase 3 trial participants achieved CHIKV neutralizing antibodies after a signle dose of their vaccine candidate, VLA1553.
Valneva, Pfizer Report Further Positive Data for Investigational Lyme Disease VaccineFebruary 4th 2022
A sub-analysis of phase 2 data compared the immunogenicity of their VLA15 vaccine in adults after administration of 2 or 3 primary series doses with the latter demonstrating a stronger response.
Contaminated Water Indicated in 40% of Major Zoonotic Disease OutbreaksNovember 2nd 2021
Analyzing the 100 largest zoonotic disease outbreaks, investigators found the most significant drivers to be water contamination, sewage management, weather conditions, and change in vector abundance.
Long-Acting Monoclonal Antibody Could Protect Against MalariaAugust 27th 2021
The National Institutes of Health (NIH) announces single injection of monoclonal antibody against the Plasmodium mosquito-borne parasite prevented malaria throughout 9 month phase 1 trial.